CalciMedica

57 articles about CalciMedica

• CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

  6/6/2023

  CalciMedica Inc. today announced the publication of preclinical data in TheJournal of Clinical Investigation (JCI) Insight that details the potential benefit of CRAC channel inhibitors for chronic pancreatitis (CP).

• CalciMedica Expands Executive Team with New Appointments

  5/23/2023

  CalciMedica Inc. today announced the appointments of Raven Jaeger, M.S., as Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, as Senior Vice President of Clinical Development.

• CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

  5/15/2023

  CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023.

• CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

  3/20/2023

  CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc.

• CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

  8/9/2022

  CalciMedica Inc. ("CalciMedica" or the "Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of preclinical data in EMBO Molecular Medicine that describes the potential utility for CRAC channel inhibitors in inflammatory bowel disease (IBD).

• CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology; Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis

  3/10/2022

  CalciMedica Inc., the CRAC channel company, announced the publication of a research paper describing how bile acid- and ethanol-mediated activation of Orai1 damages pancreatic ductal cells in AP.

• CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia

  1/20/2022

  CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, that may serve as a lead-in to its Phase 3 development program of Auxora™ in patients with critical COVID-19 pneumonia.

• CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial

  9/14/2021

  CalciMedica Inc. ("CalciMedica" or the "Company"), the CRAC channel company, today announced the results from CARDEA, a Phase 2 trial of its lead drug candidate Auxora™ in patients with severe COVID-19 pneumonia.

• CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways

  9/9/2021

  CalciMedica Inc. ("CalciMedica" or the "Company"), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 receptors, and P2X receptors as potential drug targets for diseases of the airways in the peer-reviewed Journal of Immunology.

• CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study

  6/2/2021

  CalciMedica Inc. ("CalciMedica" or the "Company), a clinical-stage biotechnology platform company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of results from the Company's completed randomized, open-label, dose-response Phase 2a study in the peer-reviewed journal Pancreas

• 

  Biopharma Execs Address the Challenges of a Post-Pandemic Workplace

  5/18/2021

  If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks.
• 

  BioSpace Movers & Shakers, March 19

  3/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• CalciMedica Announces $21 Million Series D Financing

  3/11/2021

  CalciMedica Inc. (“CalciMedica” or the “Company”), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has secured a $21 million Series D financing led by Quark Venture LP and GHS Fund (Quark Venture LP and GF Securities) and joined by previous investors,

• 

  Clinical Catch-Up: February 1 – February 5

  2/8/2021

  It was a busy week for clinical trial updates. Here’s a look.

• CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress

  2/2/2021

  CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the presentation of new clinical data from the open-label, placebo-controlled trial of Auxora™ in patients with severe COVID-19 pneumonia.

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
• 

  Vir and GSK Dose First Patient in COVID-19 Monoclonal Antibody Study and Other Pandemic Updates

  12/18/2020

  Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
• 

  Four Potential Biotech Market Movers to Watch Going into 2021

  12/17/2020

  As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.

• CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

  12/17/2020

  CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating Auxora™ in patients with severe COVID-19 pneumonia has received a recommendation to continue

• CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke

  11/13/2020

  CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of preclinical data demonstrating a pathological role for CRAC channel-mediated microglial calcium activity in ischemic brain injury in the peer-reviewed journal Stroke.